{"entity":{"id":"beijing-mabworks-biotech","kind":"company","name":"Beijing Mabworks Biotech","aka":["Beijing Mabworks Biotech Co., Ltd."],"tldr":"Beijing Mabworks Biotech is a Chinese developer in Beijing that sponsors 4 registered cancer trials of MBS314 and MBS303.","summary":"Beijing Mabworks Biotech appears on ClinicalTrials.gov as the industry sponsor of 4 interventional cancer trials (phase 1/2, 3), testing MBS314, MBS303, Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide, lenalinomide in relapsed or refractory multiple myeloma, non-hodgkin's lymphoma, follicular lymphoma and marginal zone lymphoma. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Beijing Mabworks Biotech","url":"https://clinicaltrials.gov/search?spons=Beijing%20Mabworks%20Biotech"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06232096","nct05806099","nct04834024","nct04110301"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"hq":"Beijing, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/beijing-mabworks-biotech/","neighbours":{"trial":[{"id":"nct05806099","kind":"trial","name":"A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL","route":"/trials/nct05806099/"},{"id":"nct06232096","kind":"trial","name":"A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.","route":"/trials/nct06232096/"},{"id":"nct04834024","kind":"trial","name":"MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma","route":"/trials/nct04834024/"},{"id":"nct04110301","kind":"trial","name":"MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)","route":"/trials/nct04110301/"}]}}